

Vinson&Elkins

ATTORNEYS AT LAW

VINSON & ELKINS L.L.P.
2300 FIRST CITY TOWER
1001 FANNIN STREET
HOUSTON, TEXAS 77002-6760
TELEPHONE (713) 758-2222

TEGH CENTER 1600/2900

E-Mail: tdavies@velaw.com Web: www.velaw.com

DEC 1 1 2001
Technology Center 2100

June 5, 2001

CERTIFICATE OF MAILING

I, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents; Washington, D.C. 20231 on the date below:

June 5, 20 Date

Tracey B. Davies

Office of Initial Patent Examination Customer Service Center Assistant Commissioner for Patents Washington, D.C. 20231

Re:

Continuation Application from United States Patent Application Serial No. 09/262,845, newly entitled: "Desmethylselegiline Enantiomers and their Use to Treat Drug Withdrawal Symptoms"—Blume and DiSanto (Our Ref. SOM700/13005/4-4CIP3CON)

Sir:

Enclosed is a copy of the nonprovisional application filing receipt with errors corrected. Specifically, two filing dates regarding domestic priority are incorrect. Applicant requests a corrected filing receipt indicating the corrections as marked in red on the enclosed copy.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Assistant Commissioner is hereby authorized to deduct said fees from VINSON & ELKINS L.L.P. Deposit Account No. 22-0365/SOM700/13005/4-4CIP3CON.

Respectfully submitted,

Tracey B. Davies Reg. No. 44,644

1498:3058 Encl.





SEP 2 0 2001



UNITED STATES PATENT AND TRADEMARK OFFICE


TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
WWW.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/805,281	03/13/2001	1619	728	SOM700/4- 4CIP3CON	17	21	2

CONFIRMATION NO. 2489

VINSON & ELKINS LLP 2300 First City Tower 1001 Fannin Houston, TX 77002-6760



FILING RECEIPT

OC000000000000025315

Date Mailed: 05/01/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Anthony R. DiSanto, Gobles, MI; Cheryl D. Blume, Tampa, FL;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/262,845 03/05/1999 03/15/1999 WHICH IS A CIP OF 08/679,330 07/12/1996 WHICH IS A CIP OF PCT/US96/01561 01/11/1996, AND CLAIMS BENEFIT OF 60/011,979 02/20/1996 07/31/1995 WHICH IS A CIP OF 08/372,139 01/13/1995 ABN (*) Data/inconsistent with PTO records.

and

Foreign Applications

If Required, Foreign Filing License Granted 04/30/2001

Projected Publication Date: 08/09/2001

Non-Publication Request: No

Early Publication Request: No

HECEIVED

ULU 1 2001

Technology Center 2100

Title

Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms

Preliminary Class

424

Data entry by: NGUYEN, NGAN

Team : OIPE

Date: 05/01/2001

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231